ArticleThe pharmacogenomics journal2012
Survey of US public attitudes toward pharmacogenetic testing.
Article in The pharmacogenomics journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Review and Consensus on Pharmacogenomic Testing in Psychiatry.Pharmacopsychiatry · 2021Pooled it
- Racial and ethnic differences in knowledge and attitudes about genetic testing in the US: Systematic review.Journal of genetic counseling · 2019Pooled it
- International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.Pharmacogenetics and genomics · 2019Trial
- The survey of public perception and general knowledge of genomic research and medicine in Japan conducted by the Japan Agency for Medical Research and Development.Journal of human genetics · 2019Trial
- Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.Pharmacogenomics · 2017Trial
- Genomic Medicine Among Ophthalmologists: Knowledge, Current Practice, and Barriers.Journal of personalized medicine · 2026Article
- Survey to inform personalised prescribing in a British South Asian community: pharmacogenomics and traditional medicine use.BMC medicine · 2026Article
- Public awareness, attitudes, and concerns regarding pharmacogenomics in the Kingdom of Saudi Arabia: an exploratory online cross-sectional survey.Frontiers in public health · 2026Article
- Adolescent and Young Adult Perspectives on Receiving Pathogenic or Likely Pathogenic Results in a Prospective Genomic Screening Clinical Trial.Public health genomics · 2026Article
- Article
- The prevalence of pharmacogenetic testing in the United States.Pharmacogenetics and genomics · 2025Article
- Attitudes towards a multimodal precision medicine algorithm for predicting treatment response in depression: findings from a large cross-sectional European survey.Frontiers in psychiatry · 2025Article
- A Swiss Cross-Sectional Study on Patients' Perspectives on Chronic Pain Management, Analgesic Treatment, and Genetic Susceptibility.Journal of pain research · 2025Article
- Prevalence and Factors Associated With Awareness of Precision Medicine Among Individuals With Depression and Anxiety.Cureus · 2024Article
- Disparities in Breast Cancer Care-How Factors Related to Prevention, Diagnosis, and Treatment Drive Inequity.Healthcare (Basel, Switzerland) · 2024Review
- The art of war: using genetic insights to understand and harness radiation sensitivity in hematologic malignancies.Frontiers in oncology · 2024Review
- Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors.Pharmacogenomics · 2023Article
- Patient understanding of pharmacogenomic test results in clinical care.Patient education and counseling · 2023Article
- Public perceptions of pharmacogenomic services in Ireland - Are people with chronic disease more likely to want service availability than those without? A questionnaire study.Exploratory research in clinical and social pharmacy · 2022Article
- Readiness to Accept Genetic Testing for Personalized Medicine: Survey Findings on the Role of Socio-Demographic Characteristics, Health Vulnerabilities, Perceived Genetic Risk and Personality Factors.Journal of personalized medicine · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
To assess public attitudes and interest in pharmacogenetic (PGx) testing, we conducted a random-digit-dial telephone survey of US adults, achieving a response rate of 42% (n=1139). Most respondents expressed interest in PGx testing to predict mild or serious side effects (73±3.29 and 85±2.91%, respectively), guide dosing (91%) and assist with drug selection (92%). Younger individuals (aged 18-34 years) were more likely to be interested in PGx testing to predict serious side effects (vs aged 55+ years), as well as Whites, those with a college degree, and who had experienced side effects from medications. However, most respondents (78±3.14%) were not likely to have a PGx test if there was a risk that their DNA sample or test result could be shared without their permission. Given differences in interest among some groups, providers should clearly discuss the purpose of testing, alternative testing options (if available) and policies to protect patient privacy and confidentiality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.